高危转诊中心11年间根治性膀胱切除术诊疗演变
该研究回顾性分析2006—2016年单中心814例cT1-4aN0M0膀胱癌根治性膀胱切除术资料。RARC占比由10%升至100%,新辅助化疗占29%。总体90天内再干预率8.9%、ICU入住率5.4%、死亡率2.9%;RARC在粗分析中与ICU入住、再干预和死亡风险降低相关,但加权分析后无统计学意义。
要点
- 814例根治性膀胱切除术中RARC占比由10%升至100%
- RARC组扩大盆腔淋巴结清扫72% vs ORC组19%(P<0.001)
- RARC组新膀胱构建34% vs ORC组14%(P<0.001)
核心结论
- RARC的引入与90天内ICU入住、再手术和死亡发生率降低同时出现,且未影响手术时间、盆腔淋巴结清扫范围或新膀胱使用。
研究设计与样本
- 单中心回顾性评估2006年1月至2016年12月因cT1-4aN0M0膀胱癌行开放或机器人辅助根治性膀胱切除术患者的临床资料,共814例;采用粗分析和倾向评分加权对数二项回归分析。
主要发现
- RARC占比在2006—2013年间由10%升至100%。
- 新辅助化疗总体占29%,2006—2016年间为12%—37%。
- RARC组扩大盆腔淋巴结清扫72% vs ORC组19%(P<0.001);RARC组新膀胱构建34% vs ORC组14%(P<0.001)。
- 根治性膀胱切除术后90天内再干预率8.9%、ICU入住率5.4%、死亡率2.9%。
- 粗分析中RARC与ICU入住风险降低(RR 0.42,95%CI 0.23—0.77;P=0.005)、再干预风险降低(RR 0.58,95%CI 0.37—0.90;P=0.015)和死亡风险降低(RR 0.37,95%CI 0.16—0.85;P=0.020)相关,但加权分析后这些风险降低均无统计学意义。
临床怎么用
- 原文未报告可直接用于临床决策的推荐条款或阈值。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the evolution in radical cystectomy (RC) care over 11 years at a referral centre. PATIENTS AND METHODS: The clinical data of patients undergoing either open RC (ORC) or robot-assisted RC (RARC) for cT1-4aN0M0 bladder cancer (BCa) at our centre between January 2006 and December 2016 were retrospectively evaluated. Crude and propensity score-weighted log-binomial regression analyses were conducted to assess the association between pre- and peri-operative variables and the risk of reoperation, intensive care unit (ICU) admission and death <90 days after RC. RESULTS: A total of 814 patients were considered. The percentage of RARCs performed increased (from 10% to 100%) between 2006 and 2013. Overall, 29% of the patients received neoadjuvant chemotherapy (12-37% from 2006 to 2016). Despite no differences in terms of operating time, pelvic lymph node dissection (PLND) was more commonly attempted during RARC and extended PLND was more frequently performed in the RARC group (72% vs 19%; P < 0.001). Ileal conduit was the preferred urinary diversion in both groups, and more patients in the RARC group underwent neobladder construction (34% vs 14%; P < 0.001). The overall rates of re-intervention, ICU admission and death within 90 days of RC were 8.9%, 5.4% and 2.9%, respectively. On crude analysis, RARC was associated with a reduced risk of ICU admission (relative risk [RR] 0.42, 95% confidence interval [CI] 0.23-0.77; P = 0.005), reintervention (RR 0.58, 95% CI 0.37-0.90; P = 0.015) and death (RR 0.37, 95% CI 0.16-0.85; P = 0.020); however, these risk reductions were not statistically significant on weighted analyses. CONCLUSIONS: The introduction of RARC has coincided with a reduction in the rate of ICU admission, reoperation and death within 90 days of surgery, without compromising operating time, PLND extent or neobladder utilization.
引用
- Brassetti A, Möller A, Laurin O, et al. Evolution of cystectomy care over an 11-year period in a high-volume tertiary referral centre. BJU Int. 2018. PMID: 29281852. doi:10.1111/bju.14112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。